Aurobindo Pharma看到季度利润下降,但报告财政年度利润上升10%至3 484克朗。 Aurobindo Pharma sees quarterly profit dip but reports fiscal year profit up 10% to ₹3,484 crore.

印度制药公司Aurobindo Pharma报告季度利润略有下降,从去年的907克郎降至903克郎,但财政年度利润增长10%,达到3 484克郎。 Aurobindo Pharma, an Indian drug company, reported a slight quarterly profit drop to ₹903 crore, down from ₹907 crore last year, but saw a 10% fiscal year profit increase to ₹3,484 crore. 收入每年增长9.4%,在欧洲和美国表现强劲,尽管其他市场的增长下降。 Revenue grew 9.4% annually, with strong performance in Europe and the U.S., though growth in other markets declined. 该公司预计,通过扩大能力,将继续增长。 The company expects continued growth through capacity expansions.